Table 1.
Baseline characteristics (FAS)
| HDM SCIT N = 26 | Placebo N = 28 | |
|---|---|---|
| Sex | ||
| Female | 15 | 17 |
| Males | 11 | 11 |
| Age (years, mean ± SD) | 29.8 ± 10.7 | 28.5 ± 7.1 |
| Asthma severity | ||
| Moderate persistent (step 2.2 and 2.3)* | 20 | 22 |
| Severe persistent (step 2.4)† | 6 | 6 |
| Asthma duration (years, mean ± SD) | 14.8 ± 9.7 | 14.1 ± 6.9 |
| Morning PEF‡ (mean ± SD) | 511 ± 111 | 499 ± 80.1 |
| ICS dose (μg/day) | ||
| 500 | 8 | 13 |
| 750 | 1 | 6 |
| 1000 | 11 | 3 |
| 1500 | 4 | 5 |
| 2000 | 2 | 1 |
FAS, full analysis set; HDM, house dust mite; ICS, inhaled corticosteroid; PEF, peak expiratory flow; SCIT, subcutaneous immunotherapy. All patients were caucasians.
*
According to GINA, asthma severity is moderate when the ICS dose required for asthma control is >500 μg and ≤1000 μg fluticasone propionate/day.
†
According to GINA, asthma severity is severe when the ICS dose required for asthma control is >1000 μg fluticasone propionate/day.
‡
Baseline PEF was measured during 4 weeks in January. FEV1 was <70% of predicted in all patients.